Bioventus Inc.

Bioventus Inc.

BVSNYSE / NASDAQHealthcareSmall cap

$9.88-$0.07 (-0.7%)

Last close · Data as of Nov 20, 2026

Market cap
$589.4M
P/E
25.9x
EV / EBITDA
8.4x
Revenue
$568.1M
Net margin
4.0%
ROCE
10.8%

+51.3% over the last year

Bioventus Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-29.2%
3M
-31.1%
6M
-9.7%
1Y
+51.3%
5Y
Hidden
  • This period includes a one-day price step on 8 Nov 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.07 (-0.7%) from $9.95 to $9.88 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BVS, bought on each weekday since 2021.

News & filings

What Bioventus filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -24.4% to 12.3% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • Operating profit was 2.0 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.

Read moreShow less

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Sector
Healthcare
Shares outstanding
67.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$589.4M
P/E
25.9x
P/B
3.2x
EV / EBITDA
8.4x
EV / Sales
1.5x
P/S
1.0x
52-week high
$15.26
52-week low
$6.53

Profitability

Operating margin
9.9%
Net margin
4.0%
EBITDA margin
17.5%
ROE
12.3%
ROCE
10.8%
ROIC
11.1%
ROA
3.3%
Asset turnover
0.83

Growth

Revenue
$568.1M
Revenue growth, 1Y
-0.9%
Revenue CAGR, 3Y
3.5%
Net profit growth, 1Y
-162.9%
Free cash flow
$72.1M

Solvency

Current ratio
1.70
Debt / Equity
1.60
Debt / Assets
0.43
CFO / Net profit
3.28
Cash / Market cap
8.7%

Where the revenue went

Of every $100 of FY2025 revenue, $4 was left as net income.

Bioventus Inc. income statement flow, FY2025
Bioventus Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$179.9M
RevenueGross profit$388.2M
Gross profitResearch and development$12.1M
Gross profitSelling, general and administrative$314.0M
Gross profitOther operating expenses$5.7M
Gross profitOperating income$56.3M
Operating incomePretax income$25.7M
Operating incomeInterest and other expense$30.6M
Pretax incomeTax and other$3.0M
Pretax incomeNet income$22.7M

Revenue and net profit

Revenue fell 0.9% in FY2025; net profit is the dashed line.

Bioventus Inc. revenue and net profit by fiscal year
Bioventus Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$512.1M-$158.7M
FY2023$512.3M-$156.2M
FY2024$573.3M-$36.1M
FY2025$568.1M$22.7M

Cash flows

FY2025: $74.7M from operations, $72.1M free after investment (dashed).

Bioventus Inc. operating and free cash flow by fiscal year
Bioventus Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$13.5M-$15.0M
FY2023$15.3M$8.0M
FY2024$38.8M$37.8M
FY2025$74.7M$72.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$568.1M-0.9%1Y
EBITDA
$99.2M+175.5%1Y
Net profit
$22.7M
Cash from operations
$74.7M+92.5%1Y
Free cash flow
$72.1M+90.8%1Y
Revenue CAGR, 3Y
3.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$568.1M$99.2M$22.7M$72.1M12.3%-0.9%-162.9%

Monthly returns

Month-by-month returns of BVS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$683.6M
Liabilities$455.1M
Equity$228.4M
Paid-in capital$520.9M
Retained earnings-$334.9M
Minority interest$44.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BVS highlighted.

P/E against peers

BVS trades at 25.9x earnings against a peer median of 6.6x (a 295% premium).

Not shown (no positive earnings and no EV / Sales): Beta Bionics, Inc., Ginkgo Bioworks Holdings, Inc., Altimmune, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Bioventus Inc.BVSthis companyP/E ↑ premium$589.4M25.9x3.2x12.3%8.4x
Beta Bionics, Inc.BBNX$619.0M-8.5x2.2x-25.5%-8.6x
Gyre Therapeutics, Inc.GYRE$600.6M119.5x5.7x4.7%40.3x
Phreesia, Inc.PHR$599.0M259.7x1.8x0.7%21.3x
Ginkgo Bioworks Holdings, Inc.DNA$591.2M-1.9x1.2x-61.5%-3.4x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Rigel Pharmaceuticals, Inc.RIGL$559.7M1.5x1.4x93.8%4.4x
Peer median—6.6x2.2x2.7%4.8x

Year-to-date ROI

BVS since 1 January, against earlier years.

Historical volatility

BVS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Bioventus Inc. operating margin by fiscal year
Bioventus Inc. operating margin by fiscal year
DateOperating margin
FY2022-6.8%
FY20230.4%
FY20244.0%
FY20259.9%
LineFY2025
Cost of revenueCost Of Revenue$179.9M
Gross profitGross Profit$388.2M
Operating expensesOperating Expense$331.9M
Research and developmentResearch And Development$12.1M
Selling, general and administrativeSelling General And Administration$314.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$5.7M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$5.7M
Total expensesTotal Expenses$511.8M
Pretax incomePretax Income$25.7M

Learn while you research

Academy chapters picked for Bioventus Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.60 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →